Alamea

Alamea Therapeutics was founded on the premise that the near-infrared monoamine oxidase inhibitor (NMI) targeting monoamine oxidase-A (MAO-A) has broad utility for the treatment of a variety of unmet needs in oncology. NMI has demonstrated it has the potential to be utilized as a diagnostic tumor marker for diagnosis and delineation of surgical margins for GBM patients.